Metastatic Cancer Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Active, not recruiting
- Metastatic Cancer
- Solid Tumors
- SX-682
- +3 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Enrolling by invitation
- Melanoma
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022E
B
Recruiting
- Malignant Neoplasms
- Metastatic Cancer
- Shanghai, Shanghai, China
- +4 more
2022-04-05
Apr 5, 2022M
Recruiting
- Metastatic Cancer
- +2 more
- Houston, TexasM D Anderson Cancer Center
2022-03-31
Mar 31, 2022M
Active, not recruiting
- Advanced Cancer
- +4 more
- MRTX849
- BI 1701963
- Saint Louis, Missouri
- +3 more
2022-04-04
Apr 4, 2022M
Recruiting
- Patient Reported Outcome Measures
- +7 more
- Observational Cohort
- Boston, MassachusettsMassachusetts General Hospital
2022-04-04
Apr 4, 2022L
Recruiting
- Metastatic Cancer
- Stereotactic ablative radiotherapy - Level 1
- +4 more
- London, Ontario, CanadaLondon Health Sciences Centre - London Regional Cancer Program
2022-04-04
Apr 4, 2022U
Not yet recruiting
- Metastatic Cancer
- +7 more
- Standard of Care Chemotherapy
- +7 more
- (no location specified)
2022-04-01
Apr 1, 2022C
Recruiting
- Advanced Gastrointestinal Stromal Tumors
- Metastatic Cancer
- CGT9486 plus sunitinib
- +2 more
- Duarte, California
- +6 more
2022-03-31
Mar 31, 2022T
Active, not recruiting
- Solid Tumor
- Metastatic Cancer
- Birmingham, Alabama
- +3 more
2022-03-31
Mar 31, 2022T
Not yet recruiting
- Breast Cancer Invasive
- +2 more
- Surgery
- +2 more
- Amsterdam, NetherlandsAntoni van Leeuwenhoek
2022-03-21
Mar 21, 2022P
Recruiting
- Metastatic Cancer
- Epithelial Tumor
- NG-641 in combination with Nivolumab
- Santa Monica, California
- +2 more
2022-03-16
Mar 16, 2022F
Recruiting
- Advanced Cancer
- Metastatic Cancer
- New Haven, Connecticut
- +7 more
2022-03-29
Mar 29, 2022F
Recruiting
- Advanced Cancer
- Metastatic Cancer
- Pamplona, Navarra, Spain
- +5 more
2022-03-29
Mar 29, 2022G
Recruiting
- Hepatocellular Carcinoma
- Metastatic Cancer
- GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
- Makati City, Philippines
- +3 more
2022-03-14
Mar 14, 2022I
Active, not recruiting
- Locally Advanced Solid Tumor
- +2 more
- PD-L1 t-haNK
- El Segundo, CaliforniaChan Soon-Shiong Institute for Medicine
2022-03-28
Mar 28, 2022H
Recruiting
- Sarcoma, Synovial
- +8 more
- CYCLOPHOSPHAMIDE and FLUDARABIN
- +3 more
- Jerusalem, IsraelHadassah Medical Organization
2022-03-15
Mar 15, 2022A
Not yet recruiting
- Advanced Solid Tumor
- Metastatic Cancer
- Miranda, New South Wales, Australia
- +2 more
2022-03-21
Mar 21, 2022I
Active, not recruiting
- Metastatic Cancer
- +9 more
- Mobile, Alabama
- +19 more
2022-03-14
Mar 14, 2022A
Recruiting
- Metastatic Cancer
- +2 more
- ASP9801
- Pembrolizumab
- Birmingham, Alabama
- +24 more
2022-03-20
Mar 20, 2022B
Not yet recruiting
- Head and Neck Cancer
- +4 more
- Ozuriftamab Vedotin
- PD-1 inhibitor
- (no location specified)
2022-03-08
Mar 8, 2022G
Recruiting
- Solid Tumor
- +3 more
- Los Angeles, California
- +5 more
2022-03-07
Mar 7, 2022C
Recruiting
- Head and Neck Cancer
- +2 more
- Standard arm
- Experimental arm
- Montréal, Quebec, CanadaCentre Hospitalier de l'Université de Montréal
2022-03-06
Mar 6, 2022M
Recruiting
- Advanced Cancer
- +5 more
- Atlanta, Georgia
- +1 more
2022-03-04
Mar 4, 2022